Press releases

ImmunoGenesis announces that two poster presentations on its lead development program, IMGS-001, will be presented at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022), November 8-12, 2022, in Boston, MA. The posters will be available on the ImmunoGenesis website following the conference.

ImmunoGenesis announces that President and CEO James Barlow will present on the company and its multiple immune-oncology therapeutic development programs targeting immune-excluded cold cancers at the upcoming 2022 BIO CEO & Investor Conference.

ImmunoGenesis announces that CEO James Barlow will present about the company and its multiple immune-oncology therapeutic development programs at Biotech Showcase 2022 on January 10 at 2:30 PM PST.

ImmunoGenesis announced the appointment of seasoned industry veteran Charles Schweizer, PhD, as Senior Vice President of Clinical Development. Dr. Schweizer delivers more than 25 years of oncology clinical product development, regulatory, and operations experience across pharma/biotech and contract research organizations.

ImmunoGenesis announces that preclinical data from its lead development programs were presented in six scientific posters at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021).

ImmunoGenesis announces the acceptance of six poster presentations on its lead development programs at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021).

•STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers
•Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future therapy for human glioblastoma
•Data support the advancement of ImmunoGenesis’ STING-Immune Stimulating Antibody Conjugate (ISAC) in immunologically cold tumors

ImmunoGenesis announces the appointment of seasoned industry veterans to key roles to support the expansion of the company’s R&D, clinical and business development activities. ImmunoGenesis also announces the opening of a research laboratory in JLABS @ TMC to facilitate critical translational research for its drug development programs.

Data reported in Clinical Cancer Research support the efficacy of evofosfamide in combination with checkpoint inhibition in advanced, immunologically “cold” tumors.

• ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021.
• Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer.